Botulinum Toxin Derivative Ingredient
[INQ. NO. 2011C28] BoLCA+ is made by using Methionyl r-Clostridium Botulinum Polypeptide-1 Hexapeptide-40. The Botulinum penetrates the skin layer and can act directly on the neurons of the dermis, while its main raw material demonstrates the same effect more safely and conveniently.
Dermabotul for professional users and Biotechnie for home use is a reference product that allows the user to efficiently experience the effects of Botulinum. Currently, BoLCA+ is available online and offline in Korea, and is exported to Japan, Brazil, the United States, and Europe.
Meanwhile, the company’s partners in South America and China are taking part in the commercialization of the innovative botulinum cosmeceutical products through the ODM production of private brands based on BoLCA+ products.
BPMed Cosmetic Co., Ltd. was established in 2016 for the commercialization of a new substance developed and derived from Botulinum Toxin, commonly known as Botox.
It manufactures skincare cosmetics for professional users and for home use by using Methionyl r-Clostridium Botulinum Polypeptide-1 Hexapeptide-40” (Methionyl r-Clostridium). Botulinum Polypeptide-1 Hexapeptide-40), which is the first in the world to be listed in the International Cosmetic Ingredient Dictionary (ICID).
The patents for this key material have been applied in ten countries around the world, and patent registrations have been completed in the United States, Canada, China, Republic of Korea, Japan, Russia, and Europe. Based on the trademark registration in eight countries, the company is actively engaged in overseas sales as well.
Korean-Products.com | Blog Magazine of Korean products, brands and Goods